Maxgalin ER 150 Tablet contains Pregabalin 150mg, an anticonvulsant and neuropathic pain agent primarily used to manage neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and spinal cord injury. It is also indicated as adjunctive therapy for partial-onset seizures in adults and for the management of generalized anxiety disorder in some regions. Pregabalin acts by binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, thereby reducing the release of excitatory neurotransmitters and diminishing neuronal hyperexcitability. Maxgalin ER 150 is formulated as an extended-release tablet to provide sustained plasma concentrations, allowing once-daily dosing and improved patient compliance. The medication should be administered as prescribed by a healthcare professional, with dose adjustments based on clinical response and tolerability. Common adverse effects include dizziness, somnolence, dry mouth, and peripheral edema; therefore, caution is advised in patients with renal impairment or a history of substance abuse. It is contraindicated in patients with known hypersensitivity to pregabalin or any of its excipients. Patients should be monitored regularly for efficacy and potential side effects during treatment with Maxgalin ER 150 Tablet.